#1 Clinical Trials Search in Europe

Prucalopride

Prucalopride, also known by its brand name Resolor, is a medication that has been the subject of several clinical trials investigating its efficacy and safety in treating chronic constipation. These studies have focused on various patient populations, including elderly individuals, those with hepatic or renal impairment, and patients with chronic idiopathic constipation. The trials have explored different dosages and treatment durations to determine the optimal use of prucalopride in managing this common gastrointestinal condition.

Table of Contents

What is Prucalopride?

Prucalopride, also known by its brand name Resolor[1], is a medication primarily used to treat chronic constipation. It belongs to a class of drugs called serotonin receptor agonists, which work by stimulating the movement of waste through the intestines[5].

Uses of Prucalopride

The main use of prucalopride is for the treatment of chronic idiopathic constipation. This is a condition where a person experiences long-term difficulty in passing stools, and the cause is not clearly known. Clinical trials have focused on studying prucalopride’s effectiveness in treating this condition in various populations, including:

  • Adults with chronic constipation[5]
  • Elderly patients living in nursing facilities[1]
  • Elderly patients with chronic constipation[8]

How Prucalopride Works

Prucalopride works by stimulating the natural movement of the intestines, a process known as peristalsis. It does this by activating serotonin receptors in the gut, which helps to speed up the passage of stool through the intestines. This action helps to relieve constipation and improve bowel movements[5].

Dosage and Administration

Prucalopride is typically taken orally, usually once daily before breakfast. The dosage can vary depending on the individual and the severity of their condition. Clinical trials have studied various dosages, including:

  • 0.5 mg, 1 mg, 2 mg, and 4 mg once daily[7]
  • 2 mg and 4 mg once daily for 12 weeks[5]

It’s important to note that the appropriate dosage should be determined by a healthcare professional based on individual patient factors.

Efficacy of Prucalopride

The effectiveness of prucalopride has been evaluated in several clinical trials. The main measure of efficacy in these studies was typically the proportion of patients who achieved an average of three or more spontaneous complete bowel movements (SCBMs) per week. An SCBM is a bowel movement that occurs without the use of laxatives and provides a feeling of complete emptying[5][6].

Studies have shown that prucalopride can be effective in improving bowel function and relieving symptoms associated with chronic constipation, such as straining, hard stools, and incomplete evacuation[7].

Safety and Side Effects

Clinical trials have also focused on evaluating the safety and tolerability of prucalopride. While the medication is generally well-tolerated, like all medications, it can cause side effects. Common side effects observed in studies include:

  • Headache
  • Nausea
  • Abdominal pain
  • Diarrhea

It’s important to note that the occurrence and severity of side effects can vary from person to person. Always consult with your healthcare provider about potential side effects[1][5].

Special Populations

Research has been conducted to understand how prucalopride affects different groups of people:

  • Elderly patients: Studies have specifically looked at the safety and efficacy of prucalopride in elderly patients, including those living in nursing facilities[1][8].
  • Patients with liver problems: Research has been done to understand how prucalopride is processed in the body of patients with moderate to severe liver impairment[2].
  • Patients with kidney problems: Studies have looked at how prucalopride is processed in the body of patients with various degrees of kidney impairment[9].

Ongoing Research

Clinical trials continue to investigate various aspects of prucalopride, including:

  • Long-term safety and efficacy
  • Use in different patient populations
  • Optimal dosing strategies
  • Effects on quality of life for patients with chronic constipation

These ongoing studies aim to provide more comprehensive information about the benefits and potential risks of prucalopride, helping healthcare providers make informed decisions about its use[5][6][10].

Aspect Details
Drug Name Prucalopride (Resolor)
Condition Studied Chronic Constipation
Dosages Tested 0.5 mg, 1 mg, 2 mg, 4 mg (once or twice daily)
Study Durations 4 weeks to 12 weeks
Special Populations Elderly, Hepatic Impairment, Renal Impairment
Primary Outcomes Proportion of patients with ≥3 SCBMs per week
Secondary Outcomes Symptom improvement, Quality of Life, Safety and Tolerability
Study Designs Double-blind, Placebo-controlled, Randomized
Safety Measures Adverse events, Vital signs, Laboratory tests

FAQ

  • What is prucalopride and how does it work? Prucalopride is a medication used to treat chronic constipation. It works by stimulating the movement of the intestines, helping to improve bowel function and relieve constipation symptoms.
  • What dosages of prucalopride were studied in the clinical trials? The clinical trials explored various dosages of prucalopride, including 0.5 mg, 1 mg, 2 mg, and 4 mg, given either once or twice daily. The most common dosages studied were 2 mg and 4 mg once daily.
  • How long did the treatment periods last in these clinical trials? The treatment periods in the clinical trials varied, with some lasting 4 weeks and others extending to 12 weeks. This allowed researchers to assess both short-term and longer-term effects of prucalopride.
  • Were there any special populations included in these studies? Yes, the clinical trials included various special populations. Some studies focused on elderly patients, while others investigated the effects of prucalopride in patients with moderate to severe hepatic impairment or various degrees of renal impairment.
  • What were the main outcomes measured in these clinical trials? The main outcomes measured included the proportion of patients achieving an average of 3 or more spontaneous complete bowel movements per week, changes in constipation-related symptoms, quality of life improvements, and safety and tolerability of the medication.

Ongoing Clinical Trials on Prucalopride

  • Study of prucalopride in patients with gastro-esophageal reflux disease who have incomplete response to standard acid-reducing therapy

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Prucalopride: A medication used to treat chronic constipation by stimulating intestinal movement. It is also known by the brand name Resolor.
  • Chronic Idiopathic Constipation: A long-term condition characterized by infrequent bowel movements, difficulty passing stools, or incomplete evacuation, with no known underlying cause.
  • Spontaneous Complete Bowel Movement (SCBM): A bowel movement that occurs without the use of laxatives or other interventions and results in a feeling of complete evacuation.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Hepatic Impairment: Reduced liver function that can affect how drugs are processed in the body.
  • Renal Impairment: Decreased kidney function that can impact how drugs are filtered and excreted from the body.
  • Double-Blind Study: A research design where neither the participants nor the researchers know who is receiving the actual treatment or a placebo.
  • Placebo: An inactive substance that looks like the real medication but has no therapeutic effect, used as a control in clinical trials.
  • Quality of Life (QOL): A measure of an individual's overall well-being and satisfaction with life, often used as an outcome in clinical trials.
  • Rescue Medication: A medication used to provide quick relief when symptoms worsen or breakthrough, often allowed in clinical trials under specific circumstances.

References

  1. https://clinicaltrials.gov/study/NCT00627692
  2. https://clinicaltrials.gov/study/NCT01134185
  3. https://clinicaltrials.gov/study/NCT00631813
  4. https://clinicaltrials.gov/study/NCT00617513
  5. https://clinicaltrials.gov/study/NCT00488137
  6. https://clinicaltrials.gov/study/NCT00483886
  7. https://clinicaltrials.gov/study/NCT00596596
  8. https://clinicaltrials.gov/study/NCT00487422
  9. https://clinicaltrials.gov/study/NCT01674192
  10. https://clinicaltrials.gov/study/NCT00485940